Weng Kai-Zhi, Zheng Yong-Zhi, Zhuang Shu-Quan, Chen Hai-Yun, LE Shao-Hua
Department of Pediatrics, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian Province, China.
Department of Pediatric Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Blood Medical Center, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Dec;28(6):1811-1818. doi: 10.19746/j.cnki.issn.1009-2137.2020.06.004.
To analyze the gene mutations of children with juvenile myelomonocytic leukemia (JMML) and their correlation with clinical characteristics.
The genetic mutation results and clinical data of 19 children with JMML in Fujian from January 2015 to December 2018 were collected and analyzed retrospectively. According to the results of gene mutation, they were divided into PTPN11 gene mutation group and non-PTPN11 gene mutation group, and the clinical characteristics and prognosis of children with JMML between two groups were compared.
Among the 19 children with JMML, 14 cases were male and 5 cases were female, and male/female ratio was 2.8∶1. The median age at diagnosis was 13(3-48) months, and 14 cases (73.68%) were less than 2 years old. Abdominal distension and pyrexia were the common initial symptoms, and all the children with JMML had splenomegaly. The median white blood cell count was 39.82(4.53-103.4)×10/L,and monocyte count was 4.37(1.04-23.12)×10/L. HbF was higher than the normal high value of the same age in 8 cases (42.11%). All JMML children's Philadelphia chromosome and BCR-ABL1 fusion gene were negative. Among the 19 patients, there were 1 case without any JMML related gene mutation, 7 cases (36.84%) with PTPN11 mutation, 6 cases (31.58%) with K-Ras mutation, 2 cases with NF1 mutation (10.53%), 2 cases with N-Ras mutation (10.53%), and 1 case (5.26%) with NF1 and N-Ras mutations simultaneously. Fifteen patients who only received supporting therapy all died, with a median survival time 9.2 (0.4-58.1) months. Whereas, among the four JMML children who received hematopoietic stem cell transplantation(HSCT), three cases survived and only one case died. Compared with the non-PTPN11 gene mutation group, the proportion of patients with hemoglobin F higher than the normal value of the same age was higher, and the median survival time was shorter in PTPN11 gene mutation group, and the differences were statistically significant (P=0.048 and 0.046, respectively).
JMML is more common in male infancy and toddlerhood, and the main gene mutation types are PTPN11 and Ras mutations. Because the JMML children with PTPN11 mutations show particularly rapid disease progression, if there is no timely intervention, most children die in a short period of time. Therefore, early HSCT may improve the prognosis of the children with JMML.
分析幼年型粒单核细胞白血病(JMML)患儿的基因突变情况及其与临床特征的相关性。
回顾性收集并分析2015年1月至2018年12月福建省19例JMML患儿的基因突变结果及临床资料。根据基因突变结果将其分为PTPN11基因突变组和非PTPN11基因突变组,比较两组JMML患儿的临床特征及预后。
19例JMML患儿中,男14例,女5例,男女比例为2.8∶1。诊断时的中位年龄为13(3 - 48)个月,14例(73.68%)小于2岁。腹胀和发热是常见的首发症状,所有JMML患儿均有脾肿大。白细胞计数中位数为39.82(4.53 - 103.4)×10⁹/L,单核细胞计数为4.37(1.04 - 23.12)×10⁹/L。8例(42.11%)患儿的HbF高于同年龄正常高值。所有JMML患儿的费城染色体和BCR - ABL1融合基因均为阴性。19例患者中,1例无任何JMML相关基因突变,7例(36.84%)有PTPN11突变,6例(31.58%)有K - Ras突变,2例(10.53%)有NF1突变,2例(10.53%)有N - Ras突变,1例(5.26%)同时有NF1和N - Ras突变。15例仅接受支持治疗的患者均死亡,中位生存时间为9.2(0.4 - 58.1)个月。而4例接受造血干细胞移植(HSCT)的JMML患儿中,3例存活,仅1例死亡。与非PTPN11基因突变组相比,PTPN11基因突变组中血红蛋白F高于同年龄正常值的患者比例更高,中位生存时间更短,差异有统计学意义(分别为P = 0.048和0.046)。
JMML在男性婴幼儿中更为常见,主要基因突变类型为PTPN11和Ras突变。由于PTPN11突变的JMML患儿疾病进展特别迅速,若不及时干预,大多数患儿会在短时间内死亡。因此,早期HSCT可能改善JMML患儿的预后。